coronary artery disease
Conditions
Interventions
Statin monotherapy Group:N/A
Statin + Ezetimibe Group:N/A
Statin + Aliciumab Group:N/A
Sponsors
Chinese PLA Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years; 2. Recent (within 52 weeks of alirocumab treatment Index Initiation) ACS requiring hospitalization. The ACS can be ST-elevation MI (STEMI), non-ST elevation MI (NSTEMI) or high-risk unstable angina (UA), and is defined by ischemic symptoms with unstable pattern, occurring at rest or minimal exertion within 72 hours of an unscheduled hospital admission, due to proven obstructive coronary disease and at least one of the following: (1) Elevated cardiac biomarkers; (2) Resting electrocardiogram (ECG) changes consistent with ischemia or infarction; (3) LDL-C >= 70 mg/dL (>= 1.8 mmol/L) assessed prior to patients who have been receiving any stable statin regimen within >= 4 wk prior to enrolment; OR LDL-C >= 100 mg/dL (>= 2.6 mmol/L) in patients who are statin-naive or have not been on stable statin regimen for >= 4 wk prior to enrollment; (4) Written informed consent obtained from eligible patients prior to registration enrollment in the study.
Exclusion criteria
Exclusion criteria: 1. PCSK9 inhibitors were administered within 3 months before Index Initiation; 2. Patient with any severe life-threatening conditions, including severe hepatic impairment, severe renal failure; 3. Patient with history of renal transplantation, heart transplantation; 4. Patient is a pregnant or lactating woman, or woman intending to become pregnant; 5. Other conditions unsuitable assessed by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Basic vital signs;routine blood test;Blood biochemistry;Inflammatory factor;urinalysis;myocardial damage markers;12-lead ECG;Coronary computed tomography angiography; | — |
Countries
China
Contacts
Public ContactYundai Chen
Cardiology Department of Chinese PLA Hospital
Outcome results
None listed